Delivery of Encapsulated Doxorubicin by Ultrasound-Mediated Size Reduction of Drug-Loaded Polymer Contrast Agents
- 1 January 2010
- journal article
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 57 (1), 24-28
- https://doi.org/10.1109/tbme.2009.2030497
Abstract
Low delivery efficiency combined with systemic toxicity of traditional chemotherapy provides a need for improved chemotherapeutic delivery. Within our laboratory, we have developed polymer ultrasound contrast agents (1.2-1.8 mum in diameter) containing doxorubicin (Dox) within the shell (100-150 nm). In vivo this platform is expected to circulate through the vasculature until activated at the tumor site with external focused ultrasound (US). In vitro, the agent is responsive to US and when insonated at peak positive pressure amplitudes of 0.69 MPa and above, shows dramatic size reduction, eventually reaching a mean particle size of 350 nm, presumably due to fragmentation of, or gas release from the agent. The resulting Dox-polymer particles retain the drug and are small enough to pass through the leaky pores (350-400 nm) within the tumor vasculature, providing a sustained intratumoral release of chemotherapeutic as the polymer degrades. In vivo studies using a VX2 liver tumor model have shown that the combination of the agent and US results in nearly 50% less drug delivered to the nontargeted, healthy liver ( p = 0.009) and a 110% increase ( p = 0.004) in Dox delivery to the viable peripheral tissue of the tumor, relative to the uninsonated controls. This study shows how US-mediated destruction of drug-loaded polymer contrast agent can be used to deliver encapsulated drug for potential sustained release. Penetration mechanisms of these resulting particles and their ability to provide a sustained release from the tumor interstia will be explored in the future.Keywords
This publication has 16 references indexed in Scilit:
- Comparison of in vitro and in vivo acoustic response of a novel 50:50 PLGA contrast agentUltrasonics, 2006
- New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver CancerClinical Cancer Research, 2006
- Therapeutic Use of Ultrasound Targeted Microbubble Destruction: A Review of Non-Cardiac ApplicationsUltraschall in der Medizin - European Journal of Ultrasound, 2006
- Ultrasound Enhances Gene Delivery of Human Factor IX PlasmidHuman Gene Therapy, 2005
- Intracellular Delivery of Bak BH3 Peptide by Microbubble-Enhanced UltrasoundPharmaceutical Research, 2005
- Development of a novel method for synthesis of a polymeric ultrasound contrast agentJournal of Biomedical Materials Research Part A, 2003
- A comparison of the fragmentation thresholds and inertial cavitation doses of different ultrasound contrast agentsThe Journal of the Acoustical Society of America, 2003
- Probing the structural and molecular diversity of tumor vasculatureTrends in Molecular Medicine, 2002
- Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironmentProceedings of the National Academy of Sciences, 1998
- Modulation of doxorubicin uptake by epinephrine in the VX-2 carcinomaJournal of Surgical Research, 1987